Managed Healthcare Executive5h
New Trial to Investigate Osteoporosis Drug for Type 1 Diabetes
The study explores whether Prolia/Xgeva (denosumab), a widely used therapy for osteoporosis and bone tumors, can regenerate ...
Managed Healthcare Executive23h
Defining Specialty Drugs and Upcoming Approvals to Watch | AMCP Annual 2025
Maria Lowe, Pharm.D., BCPS, associate vice president of pharmaceutical intelligence at the Institute for Clinical and ...
Managed Healthcare Executive21h
The Future of Gene Therapies and Their Impact on Payers | AMCP Annual 2025
Maria Lowe, Ph.D., associate vice president of Pharmaceutical Intelligence at Institute for Clinical and Economic Review ...
Managed Healthcare Executive22h
FDA Grants Accelerated Approval to Vanrafia for IgAN, a Rare Kidney Disease
Vanrafia reduces proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). It has a wholesale acquisition cost ...
Managed Healthcare Executive23h
The ‘Healthy Immigrant Effect’ Is Alive and Well in Kidney Disease, Study Finds
Previous research has found that immigrants have lower rates of heart disease, diabetes, dementia and other chronic health ...
Managed Healthcare Executive19h
Exploring the Wide World of GLP-1s | AMCP Annual 2025
Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...